POLYPHARMACY IN MANAGMENT OF IN-PATIENTS WITH NOVEL CORONAVIRUS DISEASE (COVID-19)
The aim. To identify polypharmacy cases and develop the ways to optimize pharmacotherapy of patients with COVID-19 hospitalized in infectious disease facilities.Materials and methods. ATC/DDD analysis with calculation of DDDs/100 bed days and a sample analysis of 500 patients’ prescriptions were per...
Main Authors: | V. I. Petrov, A. Yu. Ryazanova, N. S. Privaltseva, D. A. Nekrasov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2022-07-01
|
Series: | Фармация и фармакология (Пятигорск) |
Subjects: | |
Online Access: | https://www.pharmpharm.ru/jour/article/view/1119 |
Similar Items
-
Pharmaco-epidemiological, clinical and laboratory characteristics of drug-induced liver injury in tuberculosis
by: M. V. Koroleva
Published: (2016-02-01) -
There is a risk of kidney damage, while saving the heart (case report)
by: V. A. Batalin, et al.
Published: (2015-12-01) -
POLYPHARMACY: RESPONSE
by: S. O. Kluchnikov
Published: (2015-08-01) -
Drug-induced liver damage with cholestasis
by: A. P. Pereverzev, et al.
Published: (2020-09-01) -
Time Course of Changes in Extravascular Water of the Lung After Pneumonectomy According to the Data of Transpulmonal Thermodilution
by: V. V. Kuzkov, et al.
Published: (2006-08-01)